In what is being described as a highly unusual move, the Celgene unit at Bristol-Myers Squibb (BMY) has backed out of a $55 million settlement of a class-action lawsuit that accused the company of hiding behind a mandated safety program in order to thwart generic competition.

A patient advocate and several pension funds had claimed that Celgene exploited an FDA program that is designed to boost safety so that it could deny samples of two of its cancer drugs, including Revlimid, which generic companies need to conduct product testing in order to win regulatory approval. Consequently, patients were precluded from spending less for medications.

Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Your daily dose of news in health and medicine

Privacy Policy